Cristan A Farmer1, Audrey Thurm1, Nicole Farhat2, Simona Bianconi2, Lee Ann Keener2, Forbes D Porter3. 1. Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, 20892, USA. 2. Division of Translational Research, Eunice Kennedy Shriver National Institute of Child Health and Development, National Institutes of Health, 10 Center Drive, Bethesda, MD, 20892, USA. 3. Division of Translational Research, Eunice Kennedy Shriver National Institute of Child Health and Development, National Institutes of Health, 10 Center Drive, Bethesda, MD, 20892, USA. fdporter@mail.nih.gov.
Abstract
BACKGROUND: Niemann-Pick disease, type C1 (NPC1) is a neurodegenerative condition that arises from mutations of NPC1 and is often diagnosed in children. Recently, several drug trials have been implemented to minimize neurodegeneration, including a trial of 2-hydroxypropyl-β-cyclodextrins (VTS-270). OBJECTIVES: The current study extends findings from a previous report of 18 months of disease severity data by describing neuropsychological outcomes over the course of 36 months post-baseline. DESIGN: An open-label, dose-escalation phase I/IIa study of VTS-270 was performed in participants with NPC1 aged 4-23 years. METHODS:Fourteen participants were sequentially assigned to receive monthly initial intrathecal VTS-270 at doses of 50, 200, 300, or 400 mg per month. After initial dosing, participants were dose-escalated (to 600 or 1200 mg) as tolerated. Participants were evaluated at 6-month intervals using a standardized neuropsychological battery, including tests of cognition and adaptive behavior. A random effects model with restricted maximum likelihood estimation was constructed for each outcome, and the slope was the parameter of interest. RESULTS: Findings based on IQ scores and both standard scores and age equivalents of adaptive functioning indicate that there were not meaningful declines in these areas during the study period. The average annualized change in Full Scale IQ was negative: B = - 1.28, standard error (SE) = 0.70, t(34.2) = - 1.83, p = 0.076. The Vineland-II Adaptive Behavior Composite standard score decreased by 1.76 points per year [SE = 0.67, t(59.1) = - 2.62, p = 0.011], but annualized slopes for each of the domain age equivalents were positive: Communication [B = 0.71, SE = 3.12, t(60.7) = 0.23, p = 0.82], Socialization [B = 2.99, SE = 2.92, t(60.4) = 1.03, p = 0.30], Daily Living Skills [B = 2.76, SE = 2.76, t(60.3) = 1.18, p = 0.24], and Motor Skills [B = 1.42, SE = 0.94, t(50.5) = 1.51, p = 0.14], indicating not worsening but slower-than-average acquisition of skills. CONCLUSION: In conjunction with previous findings, these results provide support for the slowing of disease progress up to 36 months post-initiation of intrathecal VTS-270. REGISTRATION: ClinicalTrials.gov identifier NCT01747135: Hydroxypropyl Beta Cyclodextrin for Niemann-Pick type C1 Disease.
RCT Entities:
BACKGROUND:Niemann-Pick disease, type C1 (NPC1) is a neurodegenerative condition that arises from mutations of NPC1 and is often diagnosed in children. Recently, several drug trials have been implemented to minimize neurodegeneration, including a trial of 2-hydroxypropyl-β-cyclodextrins (VTS-270). OBJECTIVES: The current study extends findings from a previous report of 18 months of disease severity data by describing neuropsychological outcomes over the course of 36 months post-baseline. DESIGN: An open-label, dose-escalation phase I/IIa study of VTS-270 was performed in participants with NPC1 aged 4-23 years. METHODS: Fourteen participants were sequentially assigned to receive monthly initial intrathecal VTS-270 at doses of 50, 200, 300, or 400 mg per month. After initial dosing, participants were dose-escalated (to 600 or 1200 mg) as tolerated. Participants were evaluated at 6-month intervals using a standardized neuropsychological battery, including tests of cognition and adaptive behavior. A random effects model with restricted maximum likelihood estimation was constructed for each outcome, and the slope was the parameter of interest. RESULTS: Findings based on IQ scores and both standard scores and age equivalents of adaptive functioning indicate that there were not meaningful declines in these areas during the study period. The average annualized change in Full Scale IQ was negative: B = - 1.28, standard error (SE) = 0.70, t(34.2) = - 1.83, p = 0.076. The Vineland-II Adaptive Behavior Composite standard score decreased by 1.76 points per year [SE = 0.67, t(59.1) = - 2.62, p = 0.011], but annualized slopes for each of the domain age equivalents were positive: Communication [B = 0.71, SE = 3.12, t(60.7) = 0.23, p = 0.82], Socialization [B = 2.99, SE = 2.92, t(60.4) = 1.03, p = 0.30], Daily Living Skills [B = 2.76, SE = 2.76, t(60.3) = 1.18, p = 0.24], and Motor Skills [B = 1.42, SE = 0.94, t(50.5) = 1.51, p = 0.14], indicating not worsening but slower-than-average acquisition of skills. CONCLUSION: In conjunction with previous findings, these results provide support for the slowing of disease progress up to 36 months post-initiation of intrathecal VTS-270. REGISTRATION: ClinicalTrials.gov identifier NCT01747135: Hydroxypropyl Beta Cyclodextrin for Niemann-Pick type C1 Disease.
Authors: Nicole M Yanjanin; Jorge I Vélez; Andrea Gropman; Kelly King; Simona E Bianconi; Sandra K Conley; Carmen C Brewer; Beth Solomon; William J Pavan; Mauricio Arcos-Burgos; Marc C Patterson; Forbes D Porter Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2010-01-05 Impact factor: 3.568
Authors: F Camargo; R P Erickson; W S Garver; G S Hossain; P N Carbone; R A Heidenreich; J Blanchard Journal: Life Sci Date: 2001-11-30 Impact factor: 5.037
Authors: Charles H Vite; Jessica H Bagel; Gary P Swain; Maria Prociuk; Tracey U Sikora; Veronika M Stein; Patricia O'Donnell; Therese Ruane; Sarah Ward; Alexandra Crooks; Su Li; Elizabeth Mauldin; Susan Stellar; Marc De Meulder; Mark L Kao; Daniel S Ory; Cristin Davidson; Marie T Vanier; Steven U Walkley Journal: Sci Transl Med Date: 2015-02-25 Impact factor: 17.956
Authors: Benny Liu; Stephen D Turley; Dennis K Burns; Anna M Miller; Joyce J Repa; John M Dietschy Journal: Proc Natl Acad Sci U S A Date: 2009-01-26 Impact factor: 11.205
Authors: Cristin D Davidson; Nafeeza F Ali; Matthew C Micsenyi; Gloria Stephney; Sophie Renault; Kostantin Dobrenis; Daniel S Ory; Marie T Vanier; Steven U Walkley Journal: PLoS One Date: 2009-09-11 Impact factor: 3.240
Authors: Kanagaraj Subramanian; Darren M Hutt; Samantha M Scott; Vijay Gupta; Shu Mao; William E Balch Journal: J Biol Chem Date: 2020-04-30 Impact factor: 5.157
Authors: Dana L Cruz; Nina Pipalia; Shu Mao; Deepti Gadi; Gang Liu; Michael Grigalunas; Matthew O'Neill; Taylor R Quinn; Andi Kipper; Andreas Ekebergh; Alexander Dimmling; Carlos Gartner; Bruce J Melancon; Florence F Wagner; Edward Holson; Paul Helquist; Olaf Wiest; Frederick R Maxfield Journal: ACS Pharmacol Transl Sci Date: 2021-05-27
Authors: Chao Wang; Samantha M Scott; Shuhong Sun; Pei Zhao; Darren M Hutt; Hao Shao; Jason E Gestwicki; William E Balch Journal: Hum Mol Genet Date: 2020-01-01 Impact factor: 5.121